Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - May 20.04.2026 GMAY.LN IE000P0FL8E3 900,002.00 USD 35,397,162.55 39.330  ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the world’s largest creator of real-world evidence (RWE) for clinical decision making, today announced the availability of the largest source of novel medical content - with over 33M artifacts of evidence generated by a high-throughput, standardized observational evidence-creation workflow. Alexandria®, the Atropos Evidence™ Library, is slated to grow to two billion pEBFs by the end of 2026, exceeding all known medical evidence by 100x in volu...

LOS ANGELES--(BUSINESS WIRE)--Avem Partners (“Avem”), a private equity firm focused on lower middle market aerospace and defense businesses, today announced the completion of its acquisition of Precision Aircraft Machining Company, Inc. (“PAMCO”). True West Capital Partners, alongside several prominent family offices, and other high net-worth individuals provided capital in support of this acquisition, which included significant investment from Avem principals and several aerospace industry exe...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Momentum UCITS ETF 20.04.2026 FTMO.LN IE000CY30YV9 3,050,002.00 USD 87,284,769.77 28.618  ...

URBANA, Ill.--(BUSINESS WIRE)--Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRI...

LARKSPUR, Calif.--(BUSINESS WIRE)--AulosTM Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that new Phase 1/2 data from its ongoing study of imneskibart will be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The presentation will focus on promising results for imneskibart with and without nivolumab in checkpoint inhibitor (C...

BOSTON--(BUSINESS WIRE)--MOCA Systems, Inc. (MSI) today announced that its services division, MOCA Services, has achieved Cybersecurity Maturity Model Certification (CMMC) Level 2, validating the company’s ability to protect Controlled Unclassified Information (CUI) in accordance with Federal requirements. MSI is among the first program management and owner’s representative firms to achieve CMMC Level 2 certification, which it received after completing a rigorous audit by a Certified Third-Part...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 20.04.2026 SDVI.LN IE000YVOQ2A3 40,361.00 USD 1,160,555.62 28.754  ...

MUSCATINE, Iowa--(BUSINESS WIRE)--HNI Corporation Releases Q1 Earnings Results Conference Call...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of advanced prostate cancer, today announced that results from its ongoing Phase 2 CONVERGE-01 trial of CONV01-α will be presented at the 2026 ASCO Annual Meeting. The oral presentation, scheduled for June 1 in Chicago, will highlight data from patients with metastatic castration-resistant prostate cancer (mCRPC) prev...